Hepagene Announces FDA Clearance of IND for HPG7233 THR Beta Agonist
20 Sep 2023 //
PR NEWSWIRE
Hepagene Therapeutics to Present at the EASL Congress 2023
25 May 2023 //
PR NEWSWIRE
Hepagene Therapeutics Initiates the RISE Study, a Phase IIa Clinical Trial of HPG1860 in Patients with NASH
02 Dec 2021 //
PRESS RELEASE
Hepagene Initiates the RISE Study, of HPG1860 in Patients with NASH
02 Dec 2021 //
PRNEWSWIRE
Hepagene Therapeutics Announces Positive Results from Phase I Trial of HPG1860
23 Aug 2021 //
PRNEWSWIRE